Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience

Abstract We report our experience with venetoclax/hypomethylating agents (Ven/HMA) in 8 AML patients not candidates for intensive CT or refractory/relapsed with limited treatment options. The response rate was 50%. Venetoclax was well‐tolerated in 62.5% of the patients. Ven/HMA provides a benefit pa...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Alicia Roldán Pérez, Juan Andrés Vázquez Paganini, M. José Penalva Moreno, Eugenio Giménez Mesa, Alba Sara Vilches Moreno, Claudia Nuñez‐Torrón Stock, Regina Herráez García
Format:	Artigo
Sprog:	Inglês
Udgivet:	Wiley 2022-07-01
Serier:	Clinical Case Reports
Fag:	acute myeloid elderly hypomethylating agents leukemia Venetoclax
Online adgang:	https://doi.org/10.1002/ccr3.6116
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!